Evidence mapPaperPMID 42586992Full record

ArticleScientific reports2026

A mechanically robust and moisture-retentive hydrocolloid dressing for chronic wound management.

Laila Waled, Nour H S Habib, Alaa Farid, Roaa Ibrahim, Noha Elnagar, Soha M Kandil, Gehan Safwat, Mohamed Taha

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laila WaledFaculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, 12566, Egypt.
Nour H S HabibFaculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, 12566, Egypt.
Alaa FaridNano Gate Company, 9254 Hoda shaarawy, Al Abageyah, El Mukkatam, Cairo, 11571, Egypt.
Roaa IbrahimNano Gate Company, 9254 Hoda shaarawy, Al Abageyah, El Mukkatam, Cairo, 11571, Egypt.
Noha ElnagarDepartment of Pharmaceutical Biotechnology, Faculty of Biotechnology, Badr University, Assiut, Egypt.
Soha M KandilDepartment of Pharmaceutics and Drug Manufacturing, Faculty of Pharmacy, Modern University for Technology & Information (MTI), Cairo, 12055, Egypt. Kandil.2009@hotmail.com.
Gehan SafwatFaculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, 12566, Egypt.
Mohamed TahaNano Gate Company, 9254 Hoda shaarawy, Al Abageyah, El Mukkatam, Cairo, 11571, Egypt. prof_mtm@yahoo.com.ORCID https://orcid.org/0000-0001-7931-6611

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to their prolonged healing times and susceptibility to infection, chronic wounds pose a significant clinical challenge. In order to improve the treatment of chronic wounds, a silver-curcumin (Ag-Cur) hydrocolloid dressing was developed in this work. integrates nanotechnology with polymer-based wound dressings by using Ag-Curcumin nanoparticles (Ag-Cur NPs) as a nano filler, which were prepared and characterized using various techniques to confirm successful formation of stable silver nanoparticles with the acceptable properties, including surface Plasmon resonance (SPR), zeta potential (ZP), dynamic light scattering (DLS), Poly dispersive index (PDI), and HR-TEM. The results demonstrated the formation of Ag-Cur nanoparticles with a hydrodynamic size of 197.3 ± 0.709 nm and a zeta potential of -27.5 ± 0.603 mV. Morphological analyses via SEM and EDX revealed a porous structure with uniform nanoparticle distribution, while mechanical testing demonstrated superior tensile strength and a swelling ratio of 428.76%, surpassing commercial dressings. The hydrocolloid dressings shown high batch-to-batch reproducibility, and the Ag-Cur nanoparticles demonstrated acceptable long-term stability. Biological evaluations showed significant antimicrobial activity against pathogens such as Staphylococcus aureus, Escherichia coli, and Candida albicans, alongside potent anti-inflammatory effects (82.43% albumin denaturation inhibition at 1000 µg/mL) and substantial antibacterial, bactericidal, and anti-biofilm activity against MRSA, highlighting its promise as a multifunctional wound dressing for infection management and reducing biofilm-related healing delay. The sustained release profile, reaching 80% after 100 h, ensures prolonged therapeutic effects. Finally, with a CC

Indexed as

Bandages, HydrocolloidSilverWound HealingAnti-Infective AgentsCandida albicansColloidsCurcuminEscherichia coliHumansMetal NanoparticlesAnti-Infective AgentsColloidsCurcuminSilverAnti-inflammatoryHydrocolloidSilver NPsWound dressing

Identifiers

PMID42586992
PMCPMC13470345

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.